« Back to Record
Citation APA

Schöffski, P., Adkins, D., Blay, J. Y., Gil, T., Elias, A. A., Rutkowski, P., Pennock, G. G., Youssoufian, H., Gelderblom, H., Willey, R., & Grebennik, D. D. (2013). An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. European journal of cancer, 49(15), 3219-3228. doi:10.1016/j.ejca.2013.06.010


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/183115

Schöffski, P., Adkins, D., Blay, J. Y., Gil, T., Elias, A. A., Rutkowski, P., Pennock, G. G., Youssoufian, H., Gelderblom, H., Willey, R., & Grebennik, D. D. (2013). An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. European journal of cancer, 49(15), 3219-3228. doi:10.1016/j.ejca.2013.06.010